Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
114.860USD
+3.050+2.73%
Close 09-17 16:00（ET）
12.39BMarket Cap
250.75P/E TTM
More Details of Corcept Therapeutics Inc Company
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Corcept Therapeutics Inc Profile
Ticker SymbolCORT
Company nameCorcept Therapeutics Inc
IPO dateApr 15, 2004
CEOBelanoff (Joseph K)
Number of employees500
Security typeOrdinary Share
Fiscal year-endApr 15
Address101 Redwood Shores Parkway
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94065
Phone16506888803
Websitehttps://www.corcept.com/
Ticker SymbolCORT
IPO dateApr 15, 2004
CEOBelanoff (Joseph K)
Company Executives of Corcept Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.92M
-2.16%
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.92M
-2.16%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.40M
+2.18%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.40M
+2.18%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.28M
+1.91%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.28M
+1.91%
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
255.44K
+28.20%
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
255.44K
+28.20%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
119.66K
+0.15%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
119.66K
+0.15%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.92M
-2.16%
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.92M
-2.16%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.40M
+2.18%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.40M
+2.18%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.28M
+1.91%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.28M
+1.91%
FAQs
Who are the top five shareholders of Corcept Therapeutics Inc?
The top five shareholders of Corcept Therapeutics Inc are: Dr. Joseph K. Belanoff, M.D.
How many institutions hold shares of Corcept Therapeutics Inc (CORT)?
As of 2026Q1, 838 institutions hold shares of Corcept Therapeutics Inc, with a combined market value of approximately 76.88M, accounting for 71.62% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8457399.00.